Stockscreener 앱 받기
12.20
4.90%
0.57
시간 외 거래:
12.34
0.14
+1.15%
전일 마감가:
$11.63
열려 있는:
$11.65
하루 거래량:
559.20K
Relative Volume:
1.17
시가총액:
$194.48M
수익:
$13.11M
순이익/손실:
$-124.02M
주가수익비율:
-0.8555
EPS:
-14.261
순현금흐름:
$-107.25M
1주 성능:
+11.31%
1개월 성능:
-22.49%
6개월 성능:
-32.18%
1년 성능:
-65.06%
1일 변동 폭
$11.52
$12.59
1주일 범위
$10.03
$12.59
52주 변동 폭
$10.03
$69.97
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile
명칭
Tonix Pharmaceuticals Holding Corp
전화
212-980-9155
주소
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
12.20 | 183.64M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-04-18 | 개시 | Noble Capital Markets | Outperform |
| 2019-04-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2017-08-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2016-09-07 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 재확인 | Oppenheimer | Outperform |
| 2015-11-04 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-12 | 개시 | Oppenheimer | Outperform |
| 2015-02-17 | 재확인 | ROTH Capital | Buy |
| 2014-09-29 | 재확인 | ROTH Capital | Buy |
모두보기
토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스
Tonix Pharmaceuticals Holding Corp at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Millennium group reports 890,366 shares (5.6%) in Tonix (TNXP) - Stock Titan
Tonix Pharmaceuticals director Taylor buys $14,928 in stock By Investing.com - Investing.com South Africa
Insider Buying: Carolyn Taylor Acquires Shares of Tonix Pharmace - GuruFocus
Director Carolyn Taylor buys Tonix Pharmaceuticals (TNXP) shares in open market - Stock Titan
Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits
Tonix Pharmaceuticals Holding (TNXP) price target decreased by 15.76% to 55.42 - MSN
We're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Rate - Yahoo Finance
Tonix Pharmaceuticals Holding Corp (TNXP) Stock Price, Quote, News & History - Benzinga
Tonix Pharmaceuticals Holding Corp. Trade Ideas — TRADEGATE:TPM0 - TradingView
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026 - marketscreener.com
(TNXP) Volatility Zones as Tactical Triggers - Stock Traders Daily
Tonix CEO Seth Lederman buys $58,949 in company stock By Investing.com - Investing.com Canada
Insider Buying: Richard Stillwell Acquires Shares of Tonix Pharm - GuruFocus
Tonix Pharmaceuticals director Stillwell buys $58,250 in shares By Investing.com - Investing.com Canada
Tonix CEO Seth Lederman buys $58,949 in company stock - Investing.com UK
Tonix Pharmaceuticals director Stillwell buys $58,250 in shares - Investing.com
[Form 4] Tonix Pharmaceuticals Holding Corp. Insider Trading Activity - Stock Titan
Tonix (NASDAQ: TNXP) CEO Lederman acquires 5,000 shares in open-market buy - Stock Titan
Tonix Pharmaceuticals (TNXP) Expands Tonmya Coverage to 17 Milli - GuruFocus
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
Blue Owl Capital (OBDC) Regains Ground: Modest Gain Signals Stability Near Key LevelsBearish Sentiment - newsline.com
symbol__ Stock Quote Price and Forecast - CNN
Tonix Pharmaceuticals Expands TONMYA® Fibromyalgia Coverage to 52 Million Lives with Second Major GPO Agreement - Minichart
Tonix Pharmaceuticals stock gains on expanded TONMYA coverage By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals stock gains on expanded TONMYA coverage - Investing.com
Tonix expands commercial coverage for fibromyalgia drug TONMYA - Investing.com UK
Tonix expands commercial coverage for fibromyalgia drug TONMYA By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals secures GPO coverage for TONMYA, expanding commercial access to ~52M U.S. lives - TradingView
TONMYA coverage reaches 52M U.S. commercial lives under GPO deals (TNXP) - Stock Titan
First new fibromyalgia medicine in over 15 years now covered for 52M people - Stock Titan
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
BTS ARIRANG Exhibition at ARTE Museum Poised to Drive Las Vegas Tourism RevenueUpward Estimate Revision - The Legal Advocate
Price-Driven Insight from (TNXP) for Rule-Based Strategy - Stock Traders Daily
Tonix presents data on opioid use in fibromyalgia patients By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (TNXP) Unveils Findings on Opioid Use in F - GuruFocus
Tonix presents data on opioid use in fibromyalgia patients - Investing.com UK
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting - GlobeNewswire
Bay Area Lyme Foundation Raises $900,000 at LymeAid 2026, Presenting Inaugural Neil L. Spector, MD, Legacy Award and $300,000 in Emerging Leader Grants - GlobeNewswire Inc.
TNXP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Tonix Pharmaceuticals (TNXP) Publishes Positive Phase 1 Study Re - GuruFocus
토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
토닉스 파마슈티컬스 홀딩 주식 (TNXP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Stillwell Richard Newcomb | Director |
Jun 08 '26 |
Buy |
11.65 |
5,000 |
58,250 |
5,000 |
| LEDERMAN SETH | Chief Executive Officer |
Jun 09 '26 |
Buy |
11.79 |
5,000 |
58,950 |
9,005 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 31 '26 |
Buy |
12.62 |
5,000 |
63,100 |
20,001 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 18 '26 |
Buy |
14.89 |
15,000 |
223,350 |
15,001 |
| Taylor Carolyn E. | Director |
Aug 21 '25 |
Buy |
36.03 |
418 |
15,061 |
418 |
| Treco James | Director |
Aug 20 '25 |
Buy |
36.00 |
250 |
9,000 |
250 |
2.60%
0.94%
자본화:
|
볼륨(24시간):